Amylin Pharmaceuticals Inc. Company Profile

Aggregated data from the web about Amylin Pharmaceuticals Inc.

Company Name	Amylin Pharmaceuticals Inc.
Website	https://en.wikipedia.org
Snippet	Amylin Pharmaceuticals is a biopharmaceutical company based in San Diego, CA, that was founded in 1987.The company was engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Amylin produced three drugs: Symlin (pramlintide acetate), Byetta and Bydureon (exenatide extended-release).
Fate	Acquired by Bristol-Myers Squibb and AstraZeneca
Type	Subsidiary
Defunct	2012; 10 years ago (2012)
Founded	1987
Revenue	US$651 million (2011)[2]
Industry	Biotechnology
Products	Symlin (pramlintide)Byetta (exenatide)Bydureon (exenatide long-acting release)
Traded as	NASDAQ: AMLN
Key people	Daniel M. Bradbury[1]
Net income	US$−543 million (2011)[2]
Headquarters	San Diego, California, United States
Subsidiaries	Amylin Ohio LLC
Total assets	US$1.87 billion (2011)[2]
Total equity	US$−139 million (2011)[2]
Number of employees	1,300 (2011)[2]

Amylin Pharmaceuticals Inc. is part of the United States company list

Amylin Pharmaceuticals Inc. is part of the Biotechnology company list

Have a list of company names and need to update information? Use our Company Search tool.

Please note that Powrbot Inc does not own this content and cannot vouch for its accuracy, we simply aggregate public information for ease of research.

Want to update this profile? Please contact us here with a link to the public source verifying the edit.